about
Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicityExpression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area.Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease.Regulation of hippocampal cGMP levels as a candidate to treat cognitive deficits in Huntington's disease.Increased 90-kDa ribosomal S6 kinase (Rsk) activity is protective against mutant huntingtin toxicity.Cellular and molecular mechanisms involved in the selective vulnerability of striatal projection neurons in Huntington's disease.PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum.Postnatal development of functional dopamine, opioid and tachykinin receptors that regulate acetylcholine release from rat neostriatal slices. Effect of 6-hydroxydopamine lesion.Striatopallidal neurons are selectively protected by neurturin in an excitotoxic model of Huntington's disease.Neuroprotection of striatal neurons against kainate excitotoxicity by neurotrophins and GDNF family members.Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington's disease.Glial cell line-derived neurotrophic factor protects striatal calbindin-immunoreactive neurons from excitotoxic damage.Caveolin-1 deficiency causes cholesterol-dependent mitochondrial dysfunction and apoptotic susceptibility.Brain region- and age-dependent dysregulation of p62 and NBR1 in a mouse model of Huntington's disease.Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: role in excitotoxicity.Involvement of nerve growth factor and its receptor in the regulation of the cholinergic function in aged rats.Early down-regulation of PKCĪ“ as a pro-survival mechanism in Huntington's disease.Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.Neostriatal dopaminergic terminals prevent the GABAergic involvement in the mu- and delta-opioid inhibition of KCl-evoked endogenous acetylcholine release.Sustained increase of PKA activity in the postcommissural putamen of dyskinetic monkeys.Differential involvement of phosphatidylinositol 3-kinase and p42/p44 mitogen activated protein kinase pathways in brain-derived neurotrophic factor-induced trophic effects on cultured striatal neurons.PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model.Differential regulation of the expression of nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3 after excitotoxicity in a rat model of Huntington's disease.Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease.BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease.Activation of Elk-1 participates as a neuroprotective compensatory mechanism in models of Huntington's disease.Bax deficiency promotes an up-regulation of Bim(EL) and Bak during striatal and cortical postnatal development, and after excitotoxic injury.A brain-derived neurotrophic factor (BDNF) related system is involved in the maintenance of the polyinnervate Torpedo electric organ.Nerve growth factor and basic fibroblast growth factor protect cholinergic neurons against quinolinic acid excitotoxicity in rat neostriatum.Brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4/5 differentially regulate the phenotype and prevent degenerative changes in striatal projection neurons after excitotoxicity in vivo.The neurotrophin receptors trkA, trkB and trkC are differentially regulated after excitotoxic lesion in rat striatum.Intrastriatal grafting of a GDNF-producing cell line protects striatonigral neurons from quinolinic acid excitotoxicity in vivo.Selective resistance of tachykinin-responsive cholinergic neurons in the quinolinic acid lesioned neostriatum.Nerve growth factor and its receptor are differentially modified by chronic naltrexone treatment during rat brain development.Mice heterozygous for neurotrophin-3 display enhanced vulnerability to excitotoxicity in the striatum through increased expression of N-methyl-D-aspartate receptors.Neurokinin receptors differentially mediate endogenous acetylcholine release evoked by tachykinins in the neostriatum.Tachykinins protect cholinergic neurons from quinolinic acid excitotoxicity in striatal cultures.Unilateral neonatal hippocampal lesion alters septal innervation and trophism of the entorhinal cortex.Increased Levels of Rictor Prevent Mutant Huntingtin-Induced Neuronal Degeneration.Bax and calpain mediate excitotoxic oligodendrocyte death induced by activation of both AMPA and kainate receptors.
P50
Q28239309-8EFDDF2B-9F2F-4DAC-9BA3-528E59AB3266Q31813509-EA568583-F2E9-4404-8271-B2D83CD72F64Q34657624-943F11CE-424F-44E4-BB19-46CCB2C064A4Q34989074-DC318EA1-A38D-44B4-84B1-D29DD2907E46Q35552239-8638AC3A-25B5-48CF-99EA-3C54AAD5F3CBQ36549749-5631BC68-B85A-4C6B-B8E2-BB75DF526A21Q39800916-6E28D9A7-F7CC-4B07-8A6D-E831E047044EQ40728649-07BECD36-80F6-4DED-AA9D-8A012BA7C945Q40744948-12F9DC3F-AE55-4AD5-8964-0288C1EB2278Q40777710-D9DF54B3-D635-493C-B939-243F6F30944FQ40873179-89434DEA-0C05-413F-80E9-9944E1AFA691Q41154059-A808C812-7E25-4035-BD4A-E7C9D0113DDDQ41867772-4CBAC011-36B9-4846-BD35-D13194E4127EQ42518845-DD1E040C-2CCF-4411-B30B-9428B03EF5B6Q43280390-1C298F21-97E3-4685-B35E-D13C3436C015Q43707877-DD80D662-E31E-493E-A99C-A555F575E39BQ43848665-D4AA87F5-ADB8-4FC9-81AD-DF2AB92D2A95Q43876923-241674B5-C009-41D5-BA27-6FF3D2DE46B6Q44336418-09716BB9-410C-4672-A919-0C75DCE5EB0FQ44639804-47A5AA95-81A2-4E7E-A97B-4FEB220A4F88Q44806641-421B1D89-339D-44E3-8A9E-5B34BD3A6458Q45292704-4BB69269-43E4-40BB-8C35-1406C37096D4Q45297386-2957ACCE-B020-4703-91FA-EB3A35E5D9A4Q45303900-8D4DED6B-FE5C-4676-82B8-7B67FD994137Q45304659-C354F03F-B2CF-4DA9-83FE-C27135CD772EQ45306525-91045454-6EA6-49CC-8365-6283DB3E3D06Q46755683-2C00242D-7D37-45A3-8FA8-10AF303A55CCQ48048334-EDBFA5C8-7746-4E89-980A-8D24D9E7F998Q48129261-4476B063-8317-4D64-BD25-8D3D0C5D0430Q48172704-EE882FBF-042A-4B63-8C20-0E2727AA54C2Q48188055-B008C4BA-C062-4A35-9D63-55035969B0C5Q48284526-46F03AE6-6E3E-4BD4-A501-0B98F531E55CQ48331613-53D51C4C-9C9A-4EC3-9F44-CECD402BC291Q48347902-37B6F5EB-1321-451C-9CE4-2E7BDB497161Q48380135-F742AB05-80F3-4839-A39F-FD1E01E73622Q48686068-7562AC9A-6046-47F1-9F93-32E3A40F7EB8Q48859471-B42F685D-7601-4468-A73C-03EE8CB300FCQ48934906-AC363990-BFD0-4128-BF85-8E9EF7AB5786Q49823914-82D2130D-8903-4B76-93F8-FCD9A76E9C57Q50542236-1D344167-3642-4FDA-BAFD-3FD398301F1E
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
Õ°Õ„ÕæÕ”Õ¦ÕøÕæÕøÕ²
@hy
name
Esther Perez-Navarro
@ast
Esther Perez-Navarro
@en
Esther Perez-Navarro
@es
Esther Perez-Navarro
@nl
Esther Perez-Navarro
@sl
type
label
Esther Perez-Navarro
@ast
Esther Perez-Navarro
@en
Esther Perez-Navarro
@es
Esther Perez-Navarro
@nl
Esther Perez-Navarro
@sl
prefLabel
Esther Perez-Navarro
@ast
Esther Perez-Navarro
@en
Esther Perez-Navarro
@es
Esther Perez-Navarro
@nl
Esther Perez-Navarro
@sl
P214
P1053
F-4749-2016
P106
P1580
P21
P214
P31
P3829
P496
0000-0001-9165-6539
P7859
viaf-305873279